OncRef

Clinical Trial: NCT04536675

Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Samsung Medical Center
Information Provided By:Samsung Medical Center
Last Update Posted:2026-06-26

Study Overview

Brief Summary

This is a double-blind randomized controlled trial evaluating the effect of perioperative dual bronchodilator therapy on post-operative pulmonary function and health-related quality of life (QoL) in mild-to-moderate less symptomatic COPD patients undergoing lung cancer surgery.

Investigators hypothesized that dual bronchodilator, as compared with placebo, would prevent reduction of pulmonary function after surgical resection and improve postoperative health related QoL.

Official Title

Effect of Perioperative Fixed-dose Dual Bronchodilator Therapy on Post-operative Pulmonary Function Among Mild- to -Moderate COPD Patients Undergoing Lung Cancer Surgery

Conditions

Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Vilanterol and Umeclidinium Bromide
  • Drug: Placebo

Other Study ID Numbers

  • SMC 2020-04-153

Start Date (Actual)

2021-04-01

Primary Completion Date (Actual)

2026-04-03

Study Completion Date (Estimated)

2026-09

Enrollment (Estimated)

204

Study Type

Interventional

Phase

Phase 3